A healthy heart and circulatory system are essential to good health.
That's why at Abbott, we throw our hearts into advancing treatments
for people with cardiovascular disease. We focus on innovative
technologies that can improve the way clinicians treat people with
vascular diseases, irregular heartbeats and diseases of the heart's
valves and other structures.
The XIENCE™ Family of Drug-Eluting Stents is proven to offer
unparalleled patient outcomes during and long after percutaneous
coronary interventions (PCI).1 Implanted in over 15 million patients
and studied in 120+ clinical trials,* XIENCE™ Stent provides
consistent long-term safety data beyond 10 years.2 XIENCE™ Stent
allows interventional cardiologists (ICs) to achieve the positive
outcomes they want for their patients.
With a commitment to advancing innovative technology to ensure
people living with structural heart diseases have safe and effective
treatment options, Abbott was the first to develop transcatheter
mitral valve repair (TMVr) therapy for patients with severe mitral
The Supera™ Peripheral Stent is indicated for the superficial
femoral artery (SFA) and the proximal popliteal artery. Engineered
by a unique interwoven wire technology, this nitinol stent offers
physicians unmatched clinical outcomes across varied lesion
complexities and lengths.
CAUTION: These products are intended for use by or under the direction of a physician. Illustrations are artist's representations only and should not be considered as engineering drawings or photographs. Unless otherwise specified, all product names are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.
Leave Us A Message
For more information, leave your message. Our representative will contact you.